

**RECURRENT APHTHOUS STOMATITIS – A REVIEW****AISHWARYA J, BRUNDHA MP\***

Department of ???, Saveetha Dental College and Hospitals, Saveetha University, Chennai, Tamil Nadu, India.

Email: mpbrundha7@gmail.com

*Received: 24 November 2017, Revised and Accepted: 29 December 2017***ABSTRACT**

Aphthous stomatitis is a most common condition which affects the oral cavity and it is painful. Aphthous ulcer is characterized by the repeated occurrence of benign and non-contagious mouth ulcers. It can be caused due to triggering of T-cell-mediated immune response, by various factors. This condition is very common, affecting about 15–20% of the population. The lesions generally occur on the cheeks, lips, gums, floor, and roof of the mouth. There are three different types of aphthous stomatitis they are aphthous ulcer major, aphthous ulcer minor, and herpetiform ulcers. It can be also termed as recurrent aphthous ulcer, recurring oral aphthae, and recurrent aphthous ulceration. Informal term is canker sores.

**Keywords:** Aphthous ulcer, Benign, Non-contagious, Canker sores.**INTRODUCTION**

Recurrent aphthous stomatitis (RAS) is spontaneously occurring self-limiting ulceration in the oral cavity. It can be single or multiple lesions present in the non-keratinized parts of the oral mucosa [1]. It is characterized by painful necrotizing ulcers whose etiology is not clearly understood [2]. The lesions are shallow and covered by grayish-white pseudomembrane with an erythematous margin [3]. It is often associated with redness, swelling, and occasional bleeding from the affected areas [4]. These lesions differ from the ulceration produced by the herpes simplex virus [5]. The RAS often causes pain during eating, sleeping, and speaking [6]. In HIV patients, these ulcers are more frequently progressive, destructive, and debilitating [7].

**INCIDENCE**

Recurrent aphthous ulcer occurs in children as well as in adults. It is common and affects almost 20% of the population [8,9], mostly people belonging to higher socioeconomic status [10,11]. It occurs in adolescence and frequency of the disease decreases with age. Females are more prone to RAS than males and children [12-15]. If the ulcers occur before 5 years of age or after 30 years, then it should be considered as more complex disorder [16-19].

**TYPES**

???

**Aphthous ulcer minor (MiAU)**

This is the most common form, accounting for 80% of all cases. Oral mucosal ulcers which are discrete and <1 cm in diameter characterize this form of aphthous ulcer. MiAU infrequently presents as a small single ulcer. Lesions heal without scarring within 7–10 days. The periodicity varies between individuals, with some having longer ulcer-free episodes and some never being free from ulcers [1]. MiAU; Mikulicz ulcer occur mainly in the 10–40-year-old age group, often cause minimal symptoms. The ulcer floor is initially yellowish in color but assumes a grayish hue as healing and epithelialization proceeds. They are surrounded by an erythematous halo and some edema and are found mainly on the non-keratinized mobile mucosa of the lips, cheeks, floor of the mouth, and sulci or ventrum of the tongue. They are only uncommonly seen on the keratinized.

Mucosa of the palate or dorsum of the tongue and occur in groups of only a few ulcers (1–6) at a time [21].

**Aphthous ulcer major (MaAU)**

This is formerly known as periadenitis mucosa necrotica recurrens (PMNR). This form is less common than the others and is characterized by oval ulcers >1 cm in diameter. Occasionally, MaAU is a relatively severe form; many major aphthae may be present simultaneously. Ulcers are large and deep, may have irregular borders, and may coalesce. On healing, which may take as long as 6 weeks, ulcers can leave scarring and severe distortion of oral and pharyngeal mucosa may occur [1]. MjAU; Sutton's ulcers; PMNR are larger, of longer duration, of more frequent recurrence, and often more painful than minor ulcers. MjAUs are round or ovoid-like minor ulcers, but they are larger and associated with surrounding edema and can reach a large size, usually about 1 cm in diameter or even larger. They are found on any area of the oral mucosa, including the keratinized dorsum of the tongue or palate, occur in groups of only a few ulcers (1–6) at one time and heal slowly over 10–40 days. They recur extremely frequently may heal with scarring and are occasionally found with a raised erythrocyte sedimentation rate or plasma viscosity [21].

**Herpetiform recurrent aphthous ulcer**

This least common form (5–10% of cases) has the smallest of the aphthous ulcers, commonly <1 mm in diameter in size. The ulcers tend to occur in clusters that may consist of tens or hundreds of minute ulcers. Clusters may be small and localized, or they may be distributed throughout the soft mucosa of the oral cavity [24]. Herpetiform ulceration is found in a slightly older age group than the other forms of RAS and is found mainly in females. They begin with vesiculation which passes rapidly into multiple minute pinhead-sized discrete ulcers, which involve any oral site including the keratinized mucosa. They usually increase in size and coalesce to leave large round ragged ulcers, which heal in 10 days or longer, are often extremely painful and recur so frequently that ulceration may be virtually continuous [21].

**ETIOLOGY**

The etiology of RAS is still not understood, although many predisposing and precipitating factors have been described, namely, trauma, stress, changes in the immune system, sensitivity to certain types of food or ingested substances such as preservative agents or substances such as cinnamaldehyde or sodium lauryl sulfate present in some toothpaste, and iron, zinc, and vitamin deficiency [26,27]. Alteration of local cell-mediated immunity is often encountered in patients with RAU. Systemic T- and B-cell responses have also been reported as altered in patients with RAU [28]. Histologically, aphthous ulcers contain a mononuclear infiltrate with a fibrin coating [29]. RAS may be also one of the symptoms

of the Behçet's syndrome – a systemic, inflammatory disease, where, apart from oral and genital lesions, various general symptoms may occur. They include anterior or posterior uveitis, retinal vasculitis, erythema nodosum, cutaneous vasculitis and arthralgia, and less commonly – dysfunction of the gastrointestinal tract, nervous system, and kidneys [30-34].

Hypersensitivity reactions to exogenous antigens other than gluten do not have a significant etiological role in RAS [35]. Infectious agents such as *Helicobacter pylori* and herpes simplex virus have been investigated but have not been consistently found in aphthous ulcers [36]. It can also be due to immunological attack as in lichen planus, pemphigoid, or pemphigus; damage because of an immune defect as in HIV disease and leukemia; infections such as herpes viruses, tuberculosis, and syphilis; cancer and nutritional defects such as vitamin deficiencies and some gastrointestinal diseases [21]. There is a genetic basis behind RAS, more than 42% of patients have first-degree relatives with RAS [37]. The occurrence is 90% if both the parents are affected, but only 20% if anyone of them are only affected. It is likely to be more severe and starts at an early age in patients with family history than the ones without [38]. There are few patients whose RAS remits with oral contraceptives or during pregnancy [39]. A minority of women with RAS have cyclical oral ulceration related to the luteal phase of the menstrual cycle [40-43]. A link with autoimmune progesterone dermatitis is most unlikely [44]. Several reports document the negative association between smoking and the occurrence of RAU [6].

#### TREATMENT

Treatment for RAS is symptomatic; the goals being to decrease pain, healing time, number and size of the ulcer, and to increase disease-free periods because the main etiology is not clearly understood. Current treatment options include topical agents, systemic and topical steroids, corticosteroids, cauterization, antibiotics, mouthrinses containing active enzymes, laser treatments, and combination therapy [45].

#### Topical treatment

Amlexanox is a topical preparation that is effective in the treatment of RAS. The drug was approved by the US Food and Drug Administration in 1996 as the first treatment for aphthous ulcers in immunocompetent patients. Amlexanox is an anti-inflammatory that inhibits leukotrienes and histamines, although its exact mechanism of action in the treatment of RAS is unknown [46]. Specifically, application of amlexanox as a 5% paste to ulcerations resulted in complete resolution of pain 1.3 days sooner than no treatment and 0.7 days sooner than vehicle alone. Similarly, amlexanox reduced complete healing by 1.6 days compared with no treatment and by 0.7 days compared with vehicle alone. Ointments, unlike gels or creams, do not burn or sting when applied to ulcerations, although they adhere poorly to mucosa. Elixir forms of corticosteroids such as dexamethasone can be used as an oral rinse for patients with multiple ulcerations [5].

Other antimicrobial compounds including the mouthwash Listerine® (Warner-Lambert Consumer Healthcare, Morris Plains, NJ), whose active ingredients include a mixture of essential oils, can be used to decrease the duration and severity of RAS and to possibly reduce the occurrence of ulcerations in susceptible patients [47].

Chlorhexidine gluconate, a widely prescribed oral rinse used to reduce plaque and gingivitis, increases ulcer healing and intervals between episodes of RAS but not the recurrence rate of oral ulcerations [48].

The commonly used agents are betamethasone, fluocinonide, fluocinolone, fluticasone, and clobetasol. These agents are found to be more effective than hydrocortisone and triamcinolone, but higher risk for adrenocortical suppression and predisposition to candidiasis. So in clinical practice, triamcinolone or fluocinonide dental paste is used as topical application over the ulcers 2-3 times daily for 5 days [6].

Sodium cromoglycate lozenges may provide mild symptomatic relief (Dolby and Walker, 1975; Kowolik *et al.*, 1978), [49] but cromoglycate-




Fig. 1: ??? [20]



Fig. 2: ??? [22]




Fig. 3: ??? [23]

containing toothpaste is not beneficial [50]. Carbenoxolone sodium mouthwash reduced the severity of RAS in one study [51].

Pain relief may be achieved with 2% viscous lidocaine applied with a cotton swab several times daily, as needed [24,52]. Over-the-counter benzocaine preparations (e.g., Anbesol and Oragel) may also be used.



Fig. 4: ??? [25]

Over-the-counter agents such as orabase or zilactin-B coat aphthous ulcers and provide local protection [52].

Topical tetracyclines (e.g., aureomycin, chlortetracycline, and tetracycline) may reduce healing times and/or reduce the associated pain of RAS [53-57], but they may cause dysgeusia, oral candidosis, and a burning-like sensation of the pharynx, and they are not suitable for young children who might ingest them, with resultant tooth staining [58].

Topical immunomodulatory agents that have been suggested to be of some benefit in the management of RAS include azelastine [59], human alpha-2-interferon in cream [60,61], topical cyclosporine [62], deglycyrrhizinated licorice [63], topical 5-aminosalicylic acid [64], and prostaglandin E2 gel [65].

Other topical treatments such as sucralfate have also been proposed, which act by forming a protective film on the bottom of the oral ulcers, reducing pain, and shortening healing time [66].

#### Systemic treatment

The use of systemic agents should be reserved for patients with frequent episodes of painful and multiple ulcerations. An exception is the use of systemic corticosteroids as an acute treatment for patients [5].

Pentoxifylline is an anti-inflammatory, immunomodulatory, methylxanthine derivative that blocks neutrophil adherence and is indicated for RAS. The mode of action for pentoxifylline appears to be due to the inhibition of tumor necrosis factor and other inflammatory cytokines [67,68]. Pentoxifylline, 400 mg 3 times daily, have reported excellent results, some with long-term benefits [69,70].

Colchicine therapy is indicated in the prevention of RAS [71,72]. Doses of 0.6 mg, administered 3 times daily, appear to not only decrease the severity of RAS but also increase the intervals between episodes. At least 50% of patients appear to respond to treatment, and responders may be maintained on therapy chronically. Colchicine can cause gastrointestinal side effects, especially diarrhea, which may limit its use. Some patients can tolerate only 1 or 2 doses daily, which may limit its use as suppressive therapy. Colchicine-induced myopathy and neuropathy require monitoring for patients on long-term therapy. Bone marrow depression also has been reported, primarily in cases of acute colchicine intoxication [73].

Prednisone, at doses of 40–60 mg administered daily for 3–4 days, usually relieves inflammation and pain. Severe ulcerations may require 2 full weeks of treatment with tapering doses with ulcerations [5].

The use of dapsone in the management of RAS is especially valuable for patients who require suppressive therapy. Like colchicine, dapsone may exert its effects primarily through suppression of inflammatory cell

migration. Daily doses of 50–150 mg may be used chronically to suppress ulcer formation. Dapsone should not be administered to patients with a glucose-6-phosphate dehydrogenase deficiency and careful monitoring for hemolytic anemia is also essential. A hypersensitivity to dapsone characterized by fever, hepatitis, cholestatic jaundice, and rash is rare [74]; and agranulocytosis, another uncommon complication of dapsone, typically develops 8–12 weeks after initiation of therapy.

Thalidomide has proven to be effective at doses of 100–200 mg/day for treating RAS in patients infected with HIV and has become the drug of choice for patients with severe disease [7,75]. Less severe adverse effects, including sedation, headache, weight gain, nausea, constipation, and rash, are reversible when the drug is discontinued. Patients started on thalidomide therapy may require 2–3 months of treatment before a response is observed. A daily dose of 100–150 mg will usually suppress ulcer formation, although some patients may require higher doses. Once controlled, the dose may be tapered to alternate-day or every 3<sup>rd</sup>-day therapy [5].

Levamisole rarely causes objective clinical improvement [76], and the associated adverse effects (nausea, hyperosmia, dysgeusia, and agranulocytosis) discourage its use [77-83].

Transfer factor [84] and gammaglobulin therapy [85] have been suggested to be beneficial, but more detailed studies are needed to confirm these preliminary observations.

The reported clinical benefit of monoamine oxidase inhibitor therapy in the treatment of three patients with RAS [86,87] was probably due to accompanying dietary modifications rather than any alteration in psychological status.

#### CONCLUSION

Recurrent aphthous ulcer is the most common ulcer of the oral cavity, whose etiology is not well known. However, there are many treatments available for the prevention as well as for the cure of ulcers.

#### REFERENCES

1. Pharmacotherapy of Recurrent Aphthous Ulcers. Available from: <http://www.cyonline.org>. [Last accessed on 2014 Jul 17].
2. Herlofson BB, Barkvoll P. Sodium lauryl sulfate and recurrent aphthous ulcers. A preliminary study. *Acta Odontol Scand* 1994;52:257-9.
3. Koybasi S, Parlak AH, Serin E, Yilmaz F, Serin D. Recurrent aphthous stomatitis: Investigation of possible etiologic factors. *Am J Otolaryngol* 2006;27:229-32.
4. Riera Matute G, Riera Alonso E. Recurrent aphthous stomatitis in rheumatology. *Reumatol Clin* 2011;7:323-8.
5. Eisen D, Lynch DP. Selecting topical and systemic agents for recurrent aphthous stomatitis. *Cutis* 2001;68:201-6.
6. Scully C, Gorsky M, Lozada-Nur F. The diagnosis and management of recurrent aphthous stomatitis: A consensus approach. *J Am Dent Assoc* 2003;134:200-7.
7. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National institute of allergy and infectious diseases AIDS clinical trials group. *N Engl J Med* 1997;336:1487-93.
8. Rivera-Hidalgo F, Shulman JD, Beach MM. The association of tobacco and other factors with recurrent aphthous stomatitis in an US adult population. *Oral Dis* 2004;10:335-45.
9. Shulman JD. An exploration of point, annual, and lifetime prevalence in characterizing recurrent aphthous stomatitis in USA children and youths. *J Oral Path Med* 2004;33:558-66.
10. Shashy RG, Ridley MB. Aphthous ulcers: A difficult clinical entity. *Am J Otolaryngol* 2000;21:305-12.
11. Mimura MA, Hirota SK, Sugaya NN, Sanches JA Jr, Migliari DA. Systemic treatment in severe cases of recurrent aphthous stomatitis: An open trial. *Clinics [Sao Paulo]* 2009;64:193-8.
12. Pongissawaranun W, Laohapand PP. Epidemiologic study on recurrent aphthous stomatitis in a Thai dental patient population. *Community Dent Oral Epidemiol* 1991;19:52-3.
13. Field EA, Brookes V, Tyldesley WR. Recurrent aphthous ulceration in

- 1 children—a review. *Int J Paed Dent* 1992;2:1-10.
- 2 14. Fahmy MS. Recurrent aphthous ulcers in a mixed Arab community.
- 3 *Community Dent Oral Epidemiol* 1976;4:160-4.
- 4 15. Embil JA, Stephens RG, Mauriel R. Prevalence of recurrent herpes
- 5 labialis and aphthous ulcers among young adults on six continents. *Can*
- 6 *Med Assoc J* 1975;113:630-7.
- 7 16. Veloso FT, Carvalho J, Margo F. Immune-related systemic manifestation
- 8 of inflammatory bowel disease: Prospective study of 792 patients.
- 9 *J Clin Gastroenterol* 1996;23:29-34.
- 10 17. Schwartz T, Langevitz P, Zemer D, Gazit E, Pras M, Livnen A.
- 11 Bacher's disease in familial Mediterranean fever; Characterization
- 12 of the association between the two disease. *Semin Arthritis Rheum*
- 13 *2000;29:286-95.*
- 14 18. Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic
- 15 fever pharyngitis and aphthous stomatitis. *J Pediatr* 1987;11:43-6.
- 16 19. Paydas S, Sachin B, Zorludemir S. Sweets syndrome accompanying
- 17 leukemia; Seven cases and review of literature. *Leuk Res* 2000;24:83-6.
- 18 20. Fig-1. Available from: [http://www.pamodules.mc.duke.edu/Oral\\_Health/](http://www.pamodules.mc.duke.edu/Oral_Health/img/module1/Slide89.jpg)
- 19 [img/module1/Slide89.jpg](http://www.pamodules.mc.duke.edu/Oral_Health/img/module1/Slide89.jpg).
- 20 21. Scully C, Felix DH. Oral medicine—update for the dental practitioner.
- 21 Aphthous and other common ulcers. *Br Dent J* 2005;199:259-64.
- 22 22. Fig-2. Available from: [http://www.pamodules.mc.duke.edu/Oral\\_Health/](http://www.pamodules.mc.duke.edu/Oral_Health/img/module1/Slide93.jpg)
- 23 [img/module1/Slide93.jpg](http://www.pamodules.mc.duke.edu/Oral_Health/img/module1/Slide93.jpg).
- 24 23. Fig-3. Available from: [http://www.pamodules.mc.duke.edu/Oral\\_Health/](http://www.pamodules.mc.duke.edu/Oral_Health/img/module1/Slide97.jpg)
- 25 [img/module1/Slide97.jpg](http://www.pamodules.mc.duke.edu/Oral_Health/img/module1/Slide97.jpg).
- 26 24. Burgess JA, Johnson BD, Sommers E. Pharmacological management of
- 27 recurrent oral mucosal ulceration. *Drugs* 1990;39:54-65.
- 28 25. Fig-4. Available from: [http://www.moderndentistry.com.au/images/ulcers/](http://www.moderndentistry.com.au/images/ulcers/ulcer5.jpg)
- 29 [ulcer5.jpg](http://www.moderndentistry.com.au/images/ulcers/ulcer5.jpg).
- 30 26. Lin SS, Chou MY, Ho CC, Kao CT, Tsai CH, Wang L, *et al.* Study of the
- 31 viral infections and cytokines associated with recurrent aphthous
- 32 ulceration. *Microbes Infect* 2005;7:635-44.
- 33 27. Gallo CB, Mimura MA, Sugaya NN. Psychological stress and recurrent
- 34 aphthous stomatitis. *Clinics [Sao Paulo]* 2009;64:645-8.
- 35 28. Freedberg IM. Fitzpatrick's Dermatology in General Medicine. 5th ed.,
- 36 Vol. 1. New York: McGraw-Hill; 1999.
- 37 29. Cotran RS, Kumar V, Robbins SL. Robbins Pathologic Basis of Disease.
- 38 4th ed. Philadelphia, PA: Saunders; 1989. p. 817.
- 39 30. Field EA, Allan RB. Oral ulceration: Aetiopathogenesis, clinical
- 40 diagnosis and management in the gastrointestinal clinic. *Aliment*
- 41 *Pharmacol Ther* 2003;18:949-62.
- 42 31. Shashy RG, Ridley MB. Aphthous ulcers: A difficult clinical entity. *Am*
- 43 *J Otolaryngol* 2000;21:389-93.
- 44 32. Sun A, Hsieh RP, Chu CT, Wang JT, Liu BY, Chiang CP. Some
- 45 specific human leukocyte antigen [HLA]-DR/DQ haplotypes are
- 46 more important than individual HLA-DR and -DQ phenotypes for the
- 47 development of mucocutaneous type of Behçet's disease and for
- 48 disease shift from recurrent aphthous stomatitis to mucocutaneous type
- 49 of Behçet's disease. *J Oral Pathol Med* 2001;30:402-7.
- 50 33. Yilmaz S, Cimen KA. Familial Behçet's disease. *Rheumatol Int*
- 51 *2010;30:1107-9.*
- 52 34. Karasneh JA, Hajeer AH, Silman A, Worthington J, Ollier WE, Gul A,
- 53 *et al.* Polymorphisms in endothelial nitric oxide synthase gene are
- 54 associated with Behçet's disease. *Rheumatology* 2005;44:614-7.
- 55 35. Porter SR, Scully C, Pedersen A. Recurrent aphthous stomatitis. *Crit*
- 56 *Rev Oral Biol Med* 1998;9:306-21.
- 57 36. Chapman MS, Cimis RJ, Baughman RD. Lack of association between
- 58 aphthous ulcers and *Helicobacter pylori* [Letter]. *Arch Dermatol*
- 59 *1998;134:1634-5.*
- 60 37. Shohat-Zabarski R, Kalderon S, Klein T, Weinberger A. Close
- 61 association of HLA-B51 in persons with recurrent aphthous stomatitis.
- 62 *Oral Surg Oral Med Oral Pathol* 1992;74:455-8.
- 63 38. Ship II. Epidemiologic aspects of recurrent aphthous ulcerations. *Oral*
- 64 *Surg Oral Med Oral Pathol* 1972;33:400-6.
- 65 39. Ferguson MM, McKay Hart D, Lindsay R, Stephen KW. Progesterone
- 66 therapy for menstrually related aphthae. *Int J Oral Surg* 1978;7:463-70.
- 67 40. Dolby AE. Recurrent Mikulicz's oral aphthae—their relationship to the
- 68 menstrual cycle. *Br Dent J* 1968;124: 359-60.
- 69 41. Segal AL, Katcher AH, Brightman VJ, Miller MF. Recurrent herpes
- labialis, recurrent aphthous ulcers, and the menstrual cycle. *J Dent Res*
- 1974;53:797-803.
42. Ferguson MM, Carter J, Boyle P. An epidemiological study of factors
- associated with recurrent aphthae in women. *J Oral Med* 1984;39:212-7.
43. McCartan BE, Sullivan A. The association of menstrual cycle,
- pregnancy, and menopause with recurrent oral aphthous Barker B.
- Autoimmune progesterone stomatitis: A review and critique. *Obstet*
- Gynecol* 1992;80:455-8.
44. Moghadam BK, Hersini S. Dermatitis and stomatitis. *Oral Surg Oral*
- Med Oral Pathol Oral Radiol Endod* 1998;85:537-41.
45. Fernandes R, Tuckey T, Lam P, Allidina S, Sharifi S, Nia D. The
- Best Treatment for Aphthous Ulcers An Evidence-based study of the
- literature Department of Oral Pathology and Oral Medicine, Faculty of
- Dentistry. University of Toronto; 2013.
46. Khandwala A, Van Inwegen RG, Alfano MC. 5% amlexanox oral
- paste, a new treatment for recurrent minor aphthous ulcers, I: Clinical
- demonstration of acceleration of healing and resolution of pain. *Oral*
- Surg Oral Med Oral Pathol Oral Radiol Endod* 1997;83:222-30.
47. Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, DePaola LG,
- Siegel MA, *et al.* Effect of an antimicrobial mouthrinse on recurrent
- aphthous ulcerations. *Oral Surg Oral Med Oral Pathol* 1991;72:425-9.
48. Scully C, Porter S. Recurrent aphthous stomatitis: Current concepts
- of etiology, pathogenesis and management. *J Oral Pathol Med*
- 1989;18:21-7.
49. Dolby AE, Walker DM. A trial of cromoglycic acid in recurrent
- aphthous ulceration. *Br J Oral Surg* 1975;12:292-5.
50. Potts AJ, Frame JW, Bateman IR, Asquith P. Sodium cromoglycate
- toothpaste in the management of aphthous ulceration. *Br Dent J*
- 1984;156:250-1.
51. Poswillo D, Partridge M. Management of recurrent aphthous ulcers:
- A trial of carbenoxolone sodium mouthwash. *Br Dent J* 1984;157:55-7.
52. Grimes RM, Lynch DP. Frequently asked Questions about the Oral
- Manifestations of HIV/AIDS. JAMA HIV/AIDS Information Center.
- Available from: [http://www.ama-assn.org/special/hiv/treatmnt/updates/](http://www.ama-assn.org/special/hiv/treatmnt/updates/oral.htm#q2)
- [oral.htm#q2](http://www.ama-assn.org/special/hiv/treatmnt/updates/oral.htm#q2). [Last accessed on 2000 Apr ???].
53. Guggenheimer J, Brightman VJ, Ship II. Effect of chlortetracycline
- mouthrinses on the healing of recurrent aphthous ulcers: A double-blind
- controlled trial. *J Oral Ther Pharmacol* 1968;4:406-8.
54. Graykowski EA, Kingman A. Double-blind trial of tetracycline in
- recurrent aphthous ulceration. *J Oral Pathol* 1978;7:376-82.
55. Denman AR, Schiff AA. Recurrent oral ulceration treatment of recurrent
- aphthous ulceration of the oral cavity. *Br Dent J* 1979;1:1248-9.
56. Häyriinen-Immonen R, Sorsa T, Pettilä J, Kontinen YT, Teronen O,
- Malmström M, *et al.* Effect of tetracyclines on collagenase activity
- in patients with recurrent aphthous ulcers. *J Oral Pathol Med*
- 1994;23:269-72.
57. Henriksen V, Axell T. Treatment of recurrent aphthous ulcers with
- Aureomycin® mouthrinse or Zendium® dentifrice. *Acta Odontol Scand*
- 1985;43:47-52.
58. Porter SR, Scully C, Pedersen A. Recurrent Aphthous Stomatitis©.
- New York: Elsevier Science Inc. All Rights Reserved. 0738-081X/00/\$—
- see Front Matter 655 Avenue of the Americas; 2000.
59. Ueta E, Osaki T, Yoneda K, Yamamoto T, Kato I. A clinical trial of
- azelastine in recurrent aphthous ulceration, with an analysis of its
- actions on leukocytes. *J Oral Pathol Med* 1994;23:123-9.
60. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H. Inefficacy
- of topical alpha interferon in the treatment of oral ulcers of behçet's
- syndrome: A randomized, double blind trial. *Br J Rheumatol*
- 1991;30:395-6.
61. Hamuryudan V, Yurdakul S, Serdaroglu S, Tüzün Y, Rosenkaimer F,
- Yazici H, *et al.* Topical alpha interferon in the treatment of oral ulcers
- in behçet's syndrome: A preliminary report. *Clin Exp Rheumatol*
- 1990;8:51-4.
62. Eisen D, Ellis CN. Topical cyclosporine for oral mucosal disorders.
- J Am Acad Dermatol* 1990;23:1259-63.
63. Das SK, Das V, Gulati AK, Singh VP. Deglycyrrhized liquorice in
- aphthous ulcers. *J Assoc Physicians India* 1989;37:647.
64. Collier PM, Neill SM, Copeman PW. Topical 5-aminosalicylic acid:
- A treatment for aphthous ulcers. *Br J Dermatol* 1992;126:185-8.
65. Taylor LJ, Walker DM, Bagg J. A clinical trial of prostaglandin E2 in
- recurrent aphthous ulceration. *Br Dent J* 1993;175:125-9.
66. Rattan J, Schneider M, Arber N, Gorsky M, Dayan D. Sucralfate
- suspension as a treatment of recurrent aphthous stomatitis. *J Intern Med*
- 1994;236:341-3.
67. Bruynzeel I, Stoof TJ, Willemze R. Pentoxifylline and skin
- inflammation. *Clin Exp Dermatol* 1998;23:168-72.
68. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA.
- Pentoxifylline suppression of tumor necrosis factor gene transcription.
- Surgery* 1991;110:192-8.
69. Chandrasekhar J, Liem AA, Cox NH, Paterson AW. Oxyntoxifylline in
- the management of recurrent aphthous oral ulcers: An open clinical trial.
- Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999;87:564-7.
70. Wahba-Yahav AV. Pentoxifylline in intractable recurrent aphthous
- stomatitis: An open trial. *J Am Acad Dermatol* 1995;33:680-2.
71. Izquierdo C, Isanta C, Guillén A, Vecino R, Vallés C. Recurrent oral

- 1 aphthosis. Its treatment with colchicine. *Aten Primaria* 1989;6:358-9. 1
- 2 72. Gatot A, Tovi F. Colchicine therapy in recurrent oral ulcers [letter]. 2
- 3 *Arch Dermatol* 1984;120:994. 3
- 4 73. Harris R, Marx G, Gillett M, Kark A, Arunanthy S. Colchicine-induced 4
- 5 bone marrow suppression: Treatment with granulocyte colony- 5
- 6 stimulating factor. *J Emerg Med* 2000;18:435-40. 6
- 7 74. Prussick R, Shear NH. Dapsone hypersensitivity syndrome. *J Am Acad 7*
- 8 *Dermatol* 1996;35:346-9. 8
- 9 75. Ghigliotti G, Repetto T, Farris A, Roy MT, De Marchi R. Thalidomide: 9
- 10 Treatment of choice for aphthous ulcers in patients seropositive for 10
- 11 human immunodeficiency virus. *J Am Acad Dermatol* 1993;28:271-2. 11
- 12 76. Sun A, Chiang CP, Chiou PS, Wang JT, Liu BY, Wu YC, *et al.* 12
- 13 Immunomodulation by levamisole in patients with recurrent aphthous 13
- 14 ulcers or oral lichen planus. *J Oral Pathol Med* 1994;23:172-7. 14
- 15 77. Lehner T, Wilton JM, Ivanyi L. Double-blind crossover trial of levamisole 15
- 16 in recurrent aphthous stomatitis. *Lancet* 1976;2:926-9. 16
- 17 78. De Meyer J, Degreave M, Clarysse J, De Loose F, Peremans W. 17
- 18 Levamisole in aphthous stomatitis: Evaluation of three regimens. *Br 18*
- 19 *Med J* 1977;1:671-4. 19
- 20 79. Drinnan AJ, Fischman SL. Randomised, double-blind study of 20
- 21 levamisole in recurrent aphthous stomatitis. *J Oral Pathol* 1978;7:414-7. 21
- 22 80. Gier RE, George B, Wilson T, Rueger A, Hart JK, Quaison F, *et al.* 22
- 23 Evaluation of the therapeutic effect of levamisole in treatment of 23
- 24 recurrent aphthous stomatitis. *J Oral Pathol* 1978;7:405-13. 24
- 25 81. Kaplan B, Cardarelli C, Pinnell SR. Double-blind study of levamisole 25
- 26 in aphthous stomatitis. *J Oral Pathol* 1978;7:400-4. 26
- 27 82. Miller MF, Silvert ME, Laster LL, Green P, Ship II. Effect of levamisole 27
- 28 on the incidence and prevalence of recurrent aphthous stomatitis. 28
- 29 A double-blind clinical trial. *J Oral Pathol* 1978;7:387-92. 29
- 30 83. Olsen JA, Silverman S. Double-blind study of levamisole therapy in 30
- 31 recurrent aphthous stomatitis. *J Oral Pathol* 1978;7:393-9. 31
- 32 84. Schulkind ML, Heim LR, South MA, Jeter WS, Small PA Jr. A case 32
- 33 report of the successful treatment of recurrent aphthous stomatitis with 33
- 34 some preparations of orally administered transfer factor. *Cell Immunol* 34
- 35 1984;84:415-21. 35
- 36 85. Kaloyannides TM. Treatment of recurrent aphthous stomatitis 36
- 37 with gamma globulin: Report of five cases. *J Can Dent Assoc (Tor)* 37
- 38 1971;37:312-3. 38
- 39 86. Rosenthal SH. Does phenelzine relieve aphthous ulcers of the mouth? 39
- 40 *N Engl J Med* 1984;311:1442. 40
- 41 87. Lejonec JL, Fourestie V. Phenelzine in the treatment of aphthous ulcers 41
- 42 of the mouth. *N Engl J Med* 1985;312:859. 42
- 43 43
- 44 44
- 45 45
- 46 46
- 47 47
- 48 48
- 49 49
- 50 50
- 51 51
- 52 52
- 53 53
- 54 54
- 55 55
- 56 56
- 57 57
- 58 58
- 59 59
- 60 60
- 61 61
- 62 62
- 63 63
- 64 64
- 65 65
- 66 66
- 67 67
- 68 68
- 69 69

## Author Queries???

AQ1:Kindly provide department 26

AQ2:Kindly cite figures 1-4 in the text part and also provide caption 27

AQ3:Kindly check author name does not match with reference list 28

AQ4:Kindly provide last accessed details 29

AQ5:Kindly provide six authors before et al 30

AQ6:Kindly provide last accessed date 31

AQ7:Kindly provide text part 32